巴比食品(605338.SH):股東天津會平、天津中飲、天津巴比決定提前終止實施本次減持計劃
格隆匯8月12日丨巴比食品(605338.SH)公佈,公司於近日收到股東天津會平、天津中飲、天津巴比《股份減持計劃提前終止的吿知函》,截至吿知函出具日,天津會平通過集中競價交易方式累計減持公司股份482,600股,通過大宗交易的方式累計減持公司股份133,400股;天津中飲通過集中競價交易方式累計減持公司股份334,200股;天津巴比通過集中競價交易方式累計減持公司股份1,032,900股。基於對公司持續穩定發展的信心和對公司價值的合理判斷,天津會平、天津中飲、天津巴比決定提前終止實施本次減持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.